Hiroaki Nishimatsu
Overview
Explore the profile of Hiroaki Nishimatsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
1491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Noda M, Kaneko T, et al.
Int J Urol
. 2024 Nov;
PMID: 39575880
Background: While the occurrence of immune-related adverse events has been recognized as a prognostic marker in patients receiving immune checkpoint inhibitors, the prognostic significance of treatment-related adverse events (trAEs) in...
2.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, et al.
Int J Urol
. 2023 Sep;
30(12):1180-1186.
PMID: 37740409
Objective: Enfortumab vedotin (EV) was approved for advanced urothelial carcinoma (UC) in 2021 after the EV-301 trial showed its superiority to non-platinum-based chemotherapy as later-line treatment after platinum-based chemotherapy and...
3.
Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, et al.
Immunotherapy
. 2023 May;
15(11):827-837.
PMID: 37191002
To validate a 'drug score' that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC). We assessed oncological outcomes according to the drug score...
4.
Yamada Y, Nakagawa T, Miyakawa J, Kawai T, Taguchi S, Tabata M, et al.
World J Urol
. 2023 Feb;
41(3):767-776.
PMID: 36739339
Purpose: The prognosis of patients with pT3 upper tract urothelial carcinoma (UTUC) varies. The current study aimed to further classify patients with pT3 UTUC into different survival outcome groups based...
5.
Taguchi S, Kawai T, Nakagawa T, Miyakawa J, Kishitani K, Sugimoto K, et al.
Int J Urol
. 2022 Aug;
29(12):1462-1469.
PMID: 35996761
Objectives: Although the treatment strategy for advanced urothelial carcinoma (aUC) has drastically changed since pembrolizumab was introduced in 2017, studies revealing current survival rates in aUC are lacking. This study...
6.
Fujimoto T, Goto T, Kanematsu A, Nishimatsu H, Fujimoto M, Matsuoka T, et al.
IJU Case Rep
. 2022 Jul;
5(4):264-267.
PMID: 35795107
Introduction: Incomplete sagittal septum of the urinary bladder is an extremely rare congenital anomaly and one of the variations in bladder duplication. Herein, we report a case of incomplete sagittal...
7.
Kawai T, Taguchi S, Nakagawa T, Kamei J, Nakamura Y, Obinata D, et al.
J Immunother Cancer
. 2022 Feb;
10(2).
PMID: 35210308
Background: Several studies have reported the incidence of immune-related adverse events (irAEs) as a predictor of the efficacy of anti-programmed cell death protein 1 antibodies in patients with cancer. However,...
8.
Taguchi S, Kawai T, Nakagawa T, Nakamura Y, Kamei J, Obinata D, et al.
Sci Rep
. 2021 Aug;
11(1):15623.
PMID: 34341416
Although the albumin-to-globulin ratio (AGR) is a promising biomarker, no study has investigated its prognostic significance for advanced urothelial carcinoma (UC). This study conformed to the REporting recommendations for tumor...
9.
Yamada Y, Nakagawa T, Miyakawa J, Kawai T, Tabata M, Kaneko T, et al.
Jpn J Clin Oncol
. 2021 May;
51(10):1577-1586.
PMID: 34047345
Purpose: Renal function is frequently impaired in the patients with upper tract urothelial carcinoma. We aimed to evaluate the impact of renal function and its change after surgery on survival...
10.
Uemura H, Matsushima H, Kobayashi K, Mizusawa H, Nishimatsu H, Fizazi K, et al.
Int J Clin Oncol
. 2020 Nov;
26(3):578-590.
PMID: 33226524
Background: Darolutamide, an oral androgen receptor inhibitor, has been approved for treating nonmetastatic castration-resistant prostate cancer (nmCRPC), based on significant improvements in metastasis-free survival (MFS) in the ARAMIS clinical trial....